阿莱克萨制药(ALXA) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -0.16美元 [[[0,"-0.02"],[1,"-0.65"],[2,"-0.93"],[3,"-1.08"],[4,"-0.16"]],[[0,"2015\u4e00\u5b63\u62a5"],[1,"2015\u4e2d\u62a5"],[2,"2015\u4e09\u5b63\u62a5"],[3,"2015\u5e74\u62a5"],[4,"2016\u4e00\u5b63\u62a5"]],"\u7f8e\u5143"] 每股收益单位：美元查看明细>>	归母净利润： -336.2万美元同比增长-732.18% [[[0,"-40.40"],[1,"-1285.40"],[2,"-1829.20"],[3,"-2131.00"],[4,"-336.20"]],[[0,"2015\u4e00\u5b63\u62a5"],[1,"2015\u4e2d\u62a5"],[2,"2015\u4e09\u5b63\u62a5"],[3,"2015\u5e74\u62a5"],[4,"2016\u4e00\u5b63\u62a5"]],"\u4e07\u7f8e\u5143"] 净利润单位：万美元查看明细>>	每股净资产： -3.42美元 [[[0,"-2.66"],[1,"-3.29"],[2,"-3.54"],[3,"-3.66"],[4,"-3.42"]],[[0,"2015\u4e00\u5b63\u62a5"],[1,"2015\u4e2d\u62a5"],[2,"2015\u4e09\u5b63\u62a5"],[3,"2015\u5e74\u62a5"],[4,"2016\u4e00\u5b63\u62a5"]],"\u7f8e\u5143"] 每股净资产单位：美元查看明细>>	净资产收益率ROE(平均)：未披露
稀释每股收益： -0.16美元 [[[0,"-0.02"],[1,"-0.65"],[2,"-0.93"],[3,"-1.08"],[4,"-0.16"]],[[0,"2015\u4e00\u5b63\u62a5"],[1,"2015\u4e2d\u62a5"],[2,"2015\u4e09\u5b63\u62a5"],[3,"2015\u5e74\u62a5"],[4,"2016\u4e00\u5b63\u62a5"]],"\u7f8e\u5143"] 稀释每股收益单位：美元查看明细>>	营业收入： 72.00万美元同比增长2.13% [[[0,"70.50"],[1,"258.00"],[2,"435.30"],[3,"502.60"],[4,"72.00"]],[[0,"2015\u4e00\u5b63\u62a5"],[1,"2015\u4e2d\u62a5"],[2,"2015\u4e09\u5b63\u62a5"],[3,"2015\u5e74\u62a5"],[4,"2016\u4e00\u5b63\u62a5"]],"\u4e07\u7f8e\u5143"] 营业收入单位：万美元查看明细>>	每股现金流： -0.2美元 [[[0,"-0.66"],[1,"-1.07"],[2,"-1.46"],[3,"-1.63"],[4,"-0.20"]],[[0,"2015\u4e00\u5b63\u62a5"],[1,"2015\u4e2d\u62a5"],[2,"2015\u4e09\u5b63\u62a5"],[3,"2015\u5e74\u62a5"],[4,"2016\u4e00\u5b63\u62a5"]],"\u7f8e\u5143"] 每股现金流单位：美元查看明细>>	总资产收益率(ROA)： -26.56% [[[0,"-55.87"],[1,"-26.56"]],[[0,"2015\u5e74\u62a5"],[1,"2016\u4e00\u5b63\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为美元

近期重要事件

2021-09-06	温馨提示：美股因劳工节，9月6日休市一天
2016-05-13	详情>> 业绩披露： 2016年一季报每股收益-0.16美元,归母净利润-336.2万美元,同比去年增长-732.18%
2016-03-28	详情>> 股本变动：变动后总股本2175.06万股
2016-03-28	详情>> 业绩披露： 2015年年报每股收益-1.08美元,归母净利润-2131万美元,同比去年增长41.99%
2015-11-05	详情>> 业绩披露： 2015年三季报(累计)每股收益-0.93美元,归母净利润-1829.2万美元,同比去年增长39.08%
2015-08-06	详情>> 业绩披露： 2015年中报每股收益-0.65美元,归母净利润-1285.4万美元,同比去年增长23.02%
2015-05-11	详情>> 业绩披露： 2015年一季报每股收益-0.02美元,归母净利润-40.4万美元,同比去年增长96.24%
2015-05-07	复牌提示： 2015-05-06 16:00:16 停牌，复牌日期 2015-05-06 16:35:00
2015-04-30	股东大会：将于2015-06-23召开股东大会会议内容 ▼▲ 1. To elect seven nominees for director, each to serve until the 2016 Annual Meeting of Stockholders and until his or her successor has been elected and qualified. The Company’s Board of Directors (the “Board”) intends to present the following individuals as its nominees for election as directors: Thomas B. King Gordon Ringold, Ph.D. J. Kevin Buchi Isaac Stein Deepika R. Pakianathan, Ph.D. Joseph L. Turner J. Leighton Read, M.D. 2. To approve the Company’s 2015 Equity Incentive Plan; 3. To approve the Company’s 2015 Employee Stock Purchase Plan; 4. To approve the Company’s 2015 Non-Employee Director Stock Award Plan; 5. To ratify the selection by the Audit and Ethics Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2015; 6. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
2015-03-13	详情>> 业绩披露： 2014年年报每股收益-2.07美元,归母净利润-3673.2万美元,同比去年增长7.28%
2014-11-05	详情>> 业绩披露： 2014年三季报(累计)每股收益-1.73美元,归母净利润-3002.5万美元,同比去年增长11.49%
2014-08-07	详情>> 业绩披露： 2014年中报每股收益-0.96美元,归母净利润-1669.7万美元,同比去年增长22.38%
2014-05-05	详情>> 业绩披露： 2014年一季报每股收益-0.62美元,归母净利润-1073.5万美元,同比去年增长48.17%
2014-04-30	股东大会：将于2014-06-10召开股东大会会议内容 ▼▲ 1. To elect seven nominees for director, each to serve until the 2015 Annual Meeting of Stockholders and until his or her successor has been elected and qualified. The Company’s Board of Directors (the “Board”) intends to present the following individuals as its nominees for election as directors: Thomas B. King Gordon Ringold, Ph.D. J. Kevin Buchi Isaac Stein Deepika R. Pakianathan, Ph.D. Joseph L. Turner J. Leighton Read, M.D. 2. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement; 3. To ratify the selection by the Audit and Ethics Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2014; 4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
2014-03-25	详情>> 业绩披露： 2013年年报每股收益-2.38美元,归母净利润-3961.5万美元,同比去年增长-41.59%
2013-04-10	股东大会：将于2013-05-21召开股东大会会议内容 ▼▲ 1. To elect seven nominees for director, each to serve until the 2014 Annual Meeting of Stockholders and until his or her successor has been elected and qualified. The Company’s Board of Directors (the “Board”) intends to present the following individuals as its nominees for election as directors: Thomas B. King, Gordon Ringold, Ph.D., J. Kevin Buchi, Isaac Stein, J. Leighton Read, M.D., Deepika R. Pakianathan, Ph.D., Joseph L. Turner; 2. To approve an amendment to the 2005 Equity Incentive Plan, increasing the share reserve; 3. To approve an amendment to the 2005 Non-Employee Directors’ Stock Option Plan, increasing the share reserve; 4. To ratify the selection by the Audit and Ethics Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2013; 5. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

主营业务分析

注：通常在中报、年报时披露　

项目名称		营业收入(万美元)	收入比例(%)
按业务	递延摊销	71.2	98.89
按业务	特许权使用费	0.8	1.11

项目名称		营业收入(万美元)	收入比例(%)
按业务	递延摊销	266.6	53.04
	产品	235.5	46.86
	特许权使用费	0.5	0.10

项目名称		营业收入(万美元)	收入比例(%)
按业务	产品	256.4	46.11
	递延摊销	198.7	35.73
	里程碑	100	17.98
	特许权使用费	1	0.18

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。